Coagulation Assays

Bates, Shannon M.; Weitz, Jeffrey I.

doi:10.1161/circulationaha.104.478222

Cited by 186 publications

(213 citation statements)

References 56 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…However, its application is limited to a small number of specialized laboratories [11,12]. Several methods have been published to assess dabigatran activities, which mainly involved normal plasma samples spiked in vitro with increasing amounts of the NOAC [3,[13][14][15][16][17] or under real-life conditions [10-12, 18, 19]. The investigation aims to add to the literature the measurement of dabigatran in other biological samples than plasma such as serum and urine and to give additional data of blood samples in reallife situations, which are needed to improve medical care of acutely diseased patients.…”

Section: Introductionmentioning

confidence: 99%

Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

Du¹,

Weiß²,

Christina³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Assessing the anticoagulant effect of dabigatran may be useful in certain clinical settings. When plasma sampling is not available, serum or urine samples may provide another option for dabigatran determinations. Methods: Dabigatran was assessed in patients on treatment under real-life conditions in plasma samples by four clotting time-based assays and in plasma, serum, and urine samples by two chromogenic substrate methods. Results: The concentrations of dabigatran in patients' plasma samples were not different for the Hemoclot test (106.8 ± 89.4 ng/mL) and the ecarin clotting time (ECT, 109.5 ± 74.5 ng/mL, p = 0.58). Activated partial thromboplastin time and prothrombinase-induced clotting time showed low correlations with the other assays. Chromogenic assays measured similar concentrations as Hemoclot and ECT. For both chromogenic assays, the concentrations of dabigatran were about 70% lower in serum than in plasma samples (p < 0.0001). The intra-class coefficient (ICC, Bland-Altman analysis) was strong comparing ECT, Hemoclot thrombin inhibitor (HTI) assay, and the two chromogenic assays (r = 0.889-0.737). The ICC was low for comparisons of the chromogenic assays of serum vs. plasma values (ICC, 0.15 and 0.66). The ICC for the determination of

show abstract

Section: Introductionmentioning

confidence: 99%

Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

Du¹,

Weiß²,

Christina³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Although the LMWHs all bind to AT, they demonstrate different abilities to enhance inactivation of FXa and/or thrombin (anti-FXa:anti-FIIa ratios ranging from 2:1 to 4:1) [8].…”

Section: Introductionmentioning

confidence: 99%

“…First, since the APTT is a standard end-point clotting time assay, it can be influenced by many other coagulation variables. For example, the APTT will be prolonged by inherited or acquired coagulation factor deficiencies (including factors XII, XI, X, IX, VIII, V, and II) [8,12]. Second, more than 300 different laboratory tests are in clinical use to measure the APTT.…”

Section: Introductionmentioning

confidence: 99%

Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins

Harris

Castro-López

Hammadi

et al. 2010

Talanta

View full text Add to dashboard Cite

Fluorogenic assays have many potential advantages over traditional clot-based and chromogenic assays such as the absence of interference from a range of factor deficiencies as well as offering the possibility of assays in platelet rich plasma or whole blood. A fluorogenic anti-factor Xa (anti-FXa) assay has been developed for the determination of heparin-like anticoagulants including unfractionated heparin (UFH), low-molecular weight heparins (LMWHs), namely enoxaparin and tinzaparin, and the synthetic heparinoid danaparoid, in commercial human pooled plasma. The assay was based on the complexation of heparinspiked plasmas with exogenous FXa at a concentration of 4 nM in the presence of 0.9 µM of the fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa). Pooled plasma samples were spiked with concentrations of anticoagulants in the range 0 to 1.6 U/ml. The assay was capable of the measurement of UFH and danaparoid in the range 0-1 U/ml, and enoxaparin and tinzaparin in the range 0-0.8 U/ml and 0-0.6 U/ml, respectively. Assay percentage coefficients of variation were typically below 7 %.3

show abstract

“…PT, aPTT and fibrinogen were measured with a semi-automated technique using fibrin timer (Siemens, Behring, Marburg, Germany) [10,11].…”

Section: Methodsmentioning

confidence: 99%

Rotational Thrombo Elastometry and Standard Coagulation Tests for Hepatic Patients undergoing Major Liver Resection

Bedawy¹,

Fayed²,

Morad³

et al. 2012

J Anesthe Clinic Res

View full text Add to dashboard Cite

Coagulation Assays

Cited by 186 publications

References 56 publications

Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins

Rotational Thrombo Elastometry and Standard Coagulation Tests for Hepatic Patients undergoing Major Liver Resection

Contact Info

Product

Resources

About